Tumor Necrosis Factor (TNF) Inhibitor Drugs Market is growing rapidly with Novartis receiving the U.S. Food and Drug Administration (FDA) approval for its Cosentyx for the treatment of active non-radiographic axial spondyloarthritis
Tumor Necrosis Factor Inhibitor Drugs are drugs that have the ability to restrict or prevent the further growth of tumors. Tumor Necrosis Factor, or TNF, is a chemical neurotransmitter in the body that plays a key role in the inflammatory response of tumors. When TNF is not sufficiently regulated, tumors may grow unchecked. A TNF inhibitor, therefore, is a medical drug that inhibits the inflammatory response to tumor necrosis factor. When it comes to regional impact, North America seems to be witnessing significant growth in the tumor necrosis factor (TNF) inhibitor drugs market. This is typically due to the fact that there is the presence of key manufacturers as well as favorable reimbursement policies. On the contrary, Asia Pacific seems to be gaining robust traction since there is an emerging trend of biosimilars in emerging economies such as India, China, and South Korea. Over the years, the demand for TNF inhibitor drugs has increased, which is typically due to rising case...